Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: GlaxoSmithKline, CureVac Team For Covid-19 Jab

Wed, 03rd Feb 2021 07:48

(Alliance News) - Stock prices in London are seen opening higher on Wednesday amid optimism over more US fiscal stimulus and strong tech earnings.

In early company news, UK drugmaker GlaxoSmithKline joined the fight against the coronavirus pandemic. Plumbing and heating products supplier Ferguson updated the market over its US listing, and telecommunications provider Vodafone said its Vantage Towers initial public offering remains on track.

IG futures indicate the FTSE 100 index is to open 27.55 points higher at 6,544.20. The large-cap index closed up 50.23 points or 0.8%, at 6,516.65 on Tuesday.

GlaxoSmithKline and German biopharmaceutical company CureVac announced a new EUR150 million collaboration to jointly develop next-generation mRNA vaccines for Covid-19, with the potential for a "multi-valent approach" to address multiple emerging variants in one vaccine.

Already approved vaccines from Pfizer and Moderna use the same mRNA technology that give instructions for the body's cells to make a harmless piece of "spike proteins". The spike protein is found on the surface of the virus that causes Covid-19. This in turn makes the body trigger an immune response, offering immunity against any potential future infections. However, Pfizer and Moderna's jabs have to be administered in two doses.

Under the terms of the collaboration agreement, Glaxo will have exclusive rights to develop, manufacture, and commercialise the vaccine in all countries with the exception of Germany, Austria and Switzerland. It also will be the marketing authorisation holder for all countries other than Switzerland. Glaxo will make an upfront payment to CureVac of EUR75 million and a further milestone payment of EUR75 million, conditional on the achievement of specific milestones.

Further, Glaxo will also support the manufacture of up to 100 million doses of CureVac's first generation Covid-19 vaccine candidate CVnCoV in 2021.

The pair will contribute resources and expertise to research, develop, and manufacture a number of novel mRNA vaccine candidates, including multi-valent and monovalent approaches. Glaxo said the aim is to offer broader protection against a variety of different SARS-CoV2 variants, and to enable a quick response to new variants potentially emerging in the future.

The development programme will begin immediately, with the target of introducing the vaccine in 2022, subject to regulatory approval, Glaxo noted.

GlaxoSmithKline will report annual results at midday on Wednesday.

Ferguson said it is in the process of registering with the US Securities & Exchange Commission to enable trading of its ordinary shares in the US.

Ferguson anticipates that the additional US listing will become effective in early March and confirmed that it has applied to list its ordinary shares on the New York Stock Exchange. In addition, Ferguson will retain its premium listing on the London Stock Exchange and inclusion in the FTSE 100 index.

As a result of the additional US Listing, Ferguson's current american depositary receipt scheme managed by JPMorgan Chase Bank will be terminated.

Vodafone Group reported a fall in third-quarter revenue and said its Vantage Towers IPO remains on track.

For the third quarter ended December 31, total revenue was down 4.7% to EUR11.20 billion from EUR11.75 billion in the third quarter of 2019. Service revenue was down 3.9% to EUR9.36 billion from EUR9.73 billion. Vodafone said service revenue rose 0.4% on an organic basis.

Vodafone reaffirmed its financial 2021 guidance with adjusted earnings before interest, tax, depreciation and amortisation expected to be between EUR14.4 billion to EUR14.6 billion and free cash flow of at least EUR5 billion.

In fixed broadband, Vodafone said there has been strong demand for high-speed connectivity, with over 1.1 million next-generation network broadband customers added in Europe year-to-date, taking its total NGN broadband base to 22.6 million.

"I am pleased the group returned to service revenue growth in Q3 as a result of the continued commercial momentum across our business, including our largest market Germany. Our good trading performance underscores our confidence in the outlook for the full year. We have made further progress on our strategic priorities, including the IPO of Vantage Towers in early 2021, which remains firmly on track and will now include our 50% shareholding in the UK towers joint venture with Telefonica," said Chief Executive Officer Nick Read.

Global market sentiment was lifted on Wednesday as the US Senate took a tentative step Tuesday towards pushing through a massive economic aid package proposed by President Joe Biden, but bipartisanship was absent.

Besides USD1,400 stimulus checks, Biden's proposal would pay for programs to help schools safely reopen, accelerate Covid-19 testing and vaccine distribution, financially support small businesses, extend unemployment benefits through September, and increase food aid for those in need.

The Senate voted 50 to 49 in a straight party-line decision to begin the budget reconciliation process (one Republican did not vote). That procedural move opens the door for Democrats to push through the Covid-19 rescue package on their own, avoiding the filibuster that requires 60 votes for most legislation.

Democratic Senate majority leader Chuck Schumer said a "big bold package" is needed to avoid the long, drawn out recovery experienced in the aftermath of the 2008 global financial crisis.

"European markets are likely to open higher again, despite pan-Europe services PMI data that will inevitably be on the weaker side, and signs of rising inflation. Until they aren't, the US stimulus and global recovery themes are back in the driver's seat," said Oanda Markets analyst Jeffery Halley.

The Japanese Nikkei 225 index closed up 1.0%. In China, the Shanghai Composite ended down 0.5%, while the Hang Seng index in Hong Kong was 0.2% lower. The S&P/ASX 200 in Sydney closed up 0.9%.

Growth in China's service sector slowed in January as the amount of new work rose at the softest rate since August, mirroring the country's manufacturing sector, data from Caixin showed.

The headline seasonally adjusted business activity index fell to 52.0 index points in January from 56.3 points in December, reflecting a further loss of momentum since November, though still indicating growth. Total new work for the month rose, albeit at the slowest rate since August due to a weaker increase in export sales, in spite of recovering customer demand and new client wins.

In the US on Tuesday, Wall Street ended sharply higher, with the Dow Jones Industrial Average up 1.6%, S&P 500 up 1.4% and Nasdaq Composite up 1.6%.

Amazon.com after the New York market close reported considerably higher fourth quarter sales, with strong contributions from both product and services. The online retailer also announced that Andy Jassy will be taking over as chief executive, with founder Jeff Bezos transitioning to executive chair. Jassy will take over as CEO in the third quarter of 2021.

The Seattle, Washington-headquartered company posted total net sales of USD125.56 billion for the three months ended December 31, a sharp 44% jump from USD87.44 billion in the same quarter of 2019. This helped boost Amazon's quarterly pretax income to USD7.77 billion from USD4.05 billion.

Alphabet reported strong income growth in the fourth quarter, driven by Search and YouTube revenue. In the three months to December 31, the Google parent recorded net income of USD15.23 billion, up from the USD10.67 billion reported the year before. Diluted earnings per share rose to USD22.30 from USD15.35.

The pound was quoted at USD1.3655 on Wednesday morning, higher from USD1.3644 at the London equities close Tuesday.

The euro stood at USD1.2032, flat from USD1.2029. Against the yen, the dollar was trading at JPY105.07, little changed from JPY105.05.

Brent oil was quoted at USD57.83 a barrel Wednesday morning, up from USD57.58 at the London market close Tuesday. Gold was trading at USD1,839.65 an ounce, a touch higher from USD1,837.20 late Tuesday.

In the economics calendar on Wednesday, there are French, German, eurozone and UK service PMI readings at 0850 GMT, 0855 GMT, 0900 GMT and 0930 GMT, respectively. In the afternoon, the US service PMI print is at 1445 GMT. Elsewhere, the eurozone consumer and producer price index is due at 1000 GMT.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.